Neptune Technologies & Bioressources Inc Acquires Common Shares of Acasti Pharma Inc.
Neptune Technologies & Bioressources Inc announced that on February 10, 2012 it acquired 750,000 newly issued Class "A" common shares (the "Shares") in the capital of Acasti Pharma Inc. ("Acasti"), a subsidiary of Neptune. The Shares were acquired at a price of $1.33 CAD per Share for an aggregate consideration of $1,000,000 CAD pursuant to a subscription agreement (the "Subscription Agreement") entered into with Acasti which contained customary terms and conditions. The Subscription Agreement was entered into as part of a private placement of Shares pursuant to which Acasti raised approximately $2,000,000 CAD (the "Private Placement").
Latest Developments for Acasti Pharma Inc
Latest Key Developments in Pharmaceuticals
- Plethora Solutions Holdings PLC announces CEO Appointment
- Merck & Co Inc announces launch of new business focused on weight management interventions in U.S.
- Coronado Biosciences Inc announces management changes
- Auxilium Pharmaceuticals Inc submits application to the FDA requesting approval of xiaflex for concurrent treatment of multiple palpable cords
- Share this
- Digg this